BRAIN AND NERVOUS SYSTEM: Edited by Marc SansonPhysical approaches to treat glioblastomaLatifyan, Sofiyaa,∗; de Micheli, Ritaa,∗; Hottinger, Andreas F.a,bAuthor Information aDepartment of Oncology bDepartment of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois & Lausanne University, Lausanne, Switzerland Correspondence to Andreas F. Hottinger, MD, PhD, Departments of Oncology and Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois & Lausanne University, Lausanne, Switzerland; Centre Hospitalier Universitaire Vaudois & Lausanne University, BH 08-634, 1011 Lausanne, Switzerland. Tel: +41 21 314 1111; fax: +41 21 314 0737; e-mail: Andreas.firstname.lastname@example.org Current Opinion in Oncology: November 2020 - Volume 32 - Issue 6 - p 640-649 doi: 10.1097/CCO.0000000000000689 Buy Metrics Abstract Purpose of review Glioblastoma (GBM) patients have a poor prognosis despite the use of modern synergistic multimodal treatment strategies, with a progression-free survival estimated at 7–8 months, a median survival of 14–16 months and 5-year overall survival of 9.8%. Recent findings Physical methods hold the promise to act synergistically with classical treatments to improve the outcome of GBM patients. Fluorescent guided surgery with 5-aminolevulinic acid and tumor-treating fields therapy have already shown positive results in randomized phase III trials and have been incorporated in the standard management. Other techniques such as photodynamic therapy (PDT) and focused ultrasound, often combined whit microbubbles, are reaching clinical development. Summary Several clinical trials to evaluate the feasibility and efficacy of ultrasound devices to disrupt the blood–brain barrier are ongoing. PDT enables the creation of a safety margin or treatment of non-resecable tumors. However, randomized trials are urgently required to validate the efficacy of these promising approaches. We aim to critically review physical approaches to treat GBM, focusing on available clinical trial data. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.